66 Investor presentation First three months of 2021 Haemophilia is a rare disease wit and the market is highly competi Number of Low diagnosis and treatment rates people (000) within haemophilia 500 400 300 200 100 0 People with haemophilia Diagnosed Inhibitor Haemophilia A Haemophilia B Note: The inhibitor segment includes acquired haemophilia patients, patients with low titre inhibitors or with transient inhibitors, and patients on immune tolerance induction. Source: World Federation of Haemophilia (WFH) – Annual survey 2018; WFH: Closing the gap – achieving optimal care, Haemophilia 2012.
Download PDF file